3 of 18

Merck & Co., Inc. and Subsidiaries Percentage Change from Preceding Year Years Ended December 31 ($ in millions except per share amounts) 2000 1999 1998 2000 1999 Sales $40,363.2 $32,714.0 $26,898.2 +23% +22%(1) Research and development expenses 2,343.8 2,068.3 1,821.1 Net income 6,821.7 5,890.5 5,248.2 +16% +12% Earnings per common share assuming dilution $2.90 $2.45 $2.15 +18% +14% Dividends paid per common share $1.21 $1.10 $ .95 +10% +16% Average common shares outstanding     assuming dilution (millions) 2,353.2 2,404.6 2,441.1 Total assets 39,910.4 35,634.9 31,853.4 Capital expenditures 2,727.8 2,560.5 1,973.4 Net income as a % of average total assets 18.1% 17.5% 18.2% Number of stockholders of record 265,700 280,500 269,600 Number of employees 69,300 62,300 57,300 (1) Sales growth for 1999 includes a two point increase, attributable to supply sales to AstraZeneca LP, as a result of the 1998 restructuring of Astra Merck Inc. (2) Amounts for 1994 include a full year’s impact on results of operations of the Medco acquisition and the impact of the formation of a joint venture with Astra in November 1994. (3) Amounts for 1993 include the impact of the Medco acquisition and a restructuring charge.

3 of 18 Copyright © 1995-2001 Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved.